CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
血液系统恶性肿瘤 CAR-T 治疗后的毒性
英文原题：Toxicities following CAR-T therapy for hematological malignancies.
查看英文原题
Toxicities following CAR-T therapy for hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已改善复发/难治性血液系统恶性肿瘤患者的结局。研究还正在扩展到其他疾病，包括实体瘤、感染和自身免疫性疾病。作为一种活的药物，CAR-T 细胞与可能危及生命的免疫毒性相关，这些毒性常需要多学科团队协作处理。细胞因子释放综合征、免疫效应细胞相关神经毒性综合征、感染和血液毒性（包括血细胞减少、免疫重建功能障碍和低丙种球蛋白血症）与显著的发病率和死亡率相关。本综述采用实用方法总结关于CAR-T 毒性的当前知识，讨论其发病机制、危险因素以及预防和治疗策略。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patients with relapsed/refractory hematological malignancies. Research is also extending to other diseases, including solid tumors, infections and autoimmune disorders. As living drugs, CAR-T cells are associated with potentially life-threatening immunological toxicities, which frequently require a multidisciplinary team approach.
Cytokine-release syndrome, immune effector cell-associated neurotoxicity syndrome, infections and hematotoxicity (including cytopenias, immune reconstitution dysfunction and hypogammaglobulinemia) are associated with significant morbidity and mortality. This review takes a practical approach to summarize current knowledge on CAR-T toxicity, addressing pathogeny, risk factors, and prophylactic and therapeutic strategies.
论文信息
- 作者
- Hernani R、Benzaquén A、Solano C
- 单位
- Haematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain. Electronic address: hernani_raf@gva.es.Spain
- 文献类型
- 综述
- 期刊
- Cancer treatment reviews2022 Dec
- 原文标识
- PubMed 36308910 · DOI 10.1016/j.ctrv.2022.102479